Delcath Systems, Inc. (DCTH) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Delcath Systems, Inc. (DCTH) closed at USD 14.72 on 2026-10-14, a change of +45 % over the past year, with a market capitalization of USD 513.89M.

Delcath Systems, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Delcath Systems, Inc. key figures

Previous close

USD 14.72 (2026-10-14)

1-year change

+45 %

Market cap

USD 513.89M

Enterprise value

USD 420.45M

P/E ratio (trailing)

1,481.00

P/E ratio (forward)

329.11

EPS (trailing)

0.01

EPS (forward)

0.05

PEG ratio

1.60

Price to book

4.23

Revenue growth

20.6 %

Earnings growth

0 %

Dividend per share (trailing)

0.00

Short ratio

5.49

Employees

156

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Delcath Systems, Inc. and compare it with other stocks.